APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Granulomatosis with Polyangiitis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Granulomatosis with Polyangiitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173996290326 December 2025195 pages

Choose your research edition.

Industry ResearchGranulomatosis with Polyangiitis Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulomatosis with Polyangiitis Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Granulomatosis with Polyangiitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulomatosis with Polyangiitis Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulomatosis with Polyangiitis Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Granulomatosis with Polyangiitis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Granulomatosis with Polyangiitis Drug include Sandoz International GmbH, GlaxoSmithKline Plc, The International Biotechnology Center (IBC) Generium, Panacea Biotec Ltd, Iltoo Pharma, Genor BioPharma Co Ltd, Coherus BioSciences Inc, ChemoCentryx Inc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Granulomatosis with Polyangiitis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulomatosis with Polyangiitis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulomatosis with Polyangiitis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Granulomatosis with Polyangiitis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulomatosis with Polyangiitis Drug Segment by Company

Sandoz International GmbH

GlaxoSmithKline Plc

The International Biotechnology Center (IBC) Generium

Panacea Biotec Ltd

Iltoo Pharma

Genor BioPharma Co Ltd

Coherus BioSciences Inc

ChemoCentryx Inc

Bristol-Myers Squibb Company

Bionovis SA

Granulomatosis with Polyangiitis Drug Segment by Type

Avacopan

Benralizumab

Rituximab Biosimilar

Others

Granulomatosis with Polyangiitis Drug Segment by Application

Hospital

Clinic

Others

Granulomatosis with Polyangiitis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulomatosis with Polyangiitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulomatosis with Polyangiitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulomatosis with Polyangiitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulomatosis with Polyangiitis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Granulomatosis with Polyangiitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Granulomatosis with Polyangiitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Granulomatosis with Polyangiitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Granulomatosis with Polyangiitis Drug Industry Trends Table 2. Granulomatosis with Polyangiitis Drug Industry Drivers Table 3. Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges Table 4. Granulomatosis with Polyangiitis Drug Industry Restraints Table 5. Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Granulomatosis with Polyangiitis Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers Table 9. Global Granulomatosis with Polyangiitis Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Granulomatosis with Polyangiitis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Granulomatosis with Polyangiitis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Granulomatosis with Polyangiitis Drug Manufacturers, Product Type & Application Table 13. Global Granulomatosis with Polyangiitis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Granulomatosis with Polyangiitis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Avacopan Table 17. Major Manufacturers of Benralizumab Table 18. Major Manufacturers of Rituximab Biosimilar Table 19. Major Manufacturers of Others Table 20. Global Granulomatosis with Polyangiitis Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 22. Global Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (W Units) Table 23. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2021-2026) Table 24. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2027-2032) Table 25. Global Granulomatosis with Polyangiitis Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2026) & (W Units) Table 27. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2027-2032) & (W Units) Table 28. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2021-2026) Table 29. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Granulomatosis with Polyangiitis Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 35. Global Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (W Units) Table 36. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2021-2026) Table 37. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2027-2032) Table 38. Global Granulomatosis with Polyangiitis Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2026) & (W Units) Table 40. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2027-2032) & (W Units) Table 41. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2021-2026) Table 42. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2027-2032) Table 43. Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2026) & (W Units) Table 45. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2021-2026) Table 46. Global Granulomatosis with Polyangiitis Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 47. Global Granulomatosis with Polyangiitis Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Granulomatosis with Polyangiitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 49. North America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 50. North America Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 51. Europe Granulomatosis with Polyangiitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 53. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 54. Asia Pacific Granulomatosis with Polyangiitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 56. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 57. South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 59. South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 60. Global Granulomatosis with Polyangiitis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2021-2026) Table 64. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2027-2032) Table 65. Sandoz International GmbH Company Information Table 66. Sandoz International GmbH Business Overview Table 67. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio Table 69. Sandoz International GmbH Recent Development Table 70. GlaxoSmithKline Plc Company Information Table 71. GlaxoSmithKline Plc Business Overview Table 72. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio Table 74. GlaxoSmithKline Plc Recent Development Table 75. The International Biotechnology Center (IBC) Generium Company Information Table 76. The International Biotechnology Center (IBC) Generium Business Overview Table 77. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio Table 79. The International Biotechnology Center (IBC) Generium Recent Development Table 80. Panacea Biotec Ltd Company Information Table 81. Panacea Biotec Ltd Business Overview Table 82. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio Table 84. Panacea Biotec Ltd Recent Development Table 85. Iltoo Pharma Company Information Table 86. Iltoo Pharma Business Overview Table 87. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio Table 89. Iltoo Pharma Recent Development Table 90. Genor BioPharma Co Ltd Company Information Table 91. Genor BioPharma Co Ltd Business Overview Table 92. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio Table 94. Genor BioPharma Co Ltd Recent Development Table 95. Coherus BioSciences Inc Company Information Table 96. Coherus BioSciences Inc Business Overview Table 97. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio Table 99. Coherus BioSciences Inc Recent Development Table 100. ChemoCentryx Inc Company Information Table 101. ChemoCentryx Inc Business Overview Table 102. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio Table 104. ChemoCentryx Inc Recent Development Table 105. Bristol-Myers Squibb Company Company Information Table 106. Bristol-Myers Squibb Company Business Overview Table 107. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio Table 109. Bristol-Myers Squibb Company Recent Development Table 110. Bionovis SA Company Information Table 111. Bionovis SA Business Overview Table 112. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio Table 114. Bionovis SA Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Granulomatosis with Polyangiitis Drug Distributors List Table 118. Granulomatosis with Polyangiitis Drug Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Granulomatosis with Polyangiitis Drug Product Image Figure 2. Global Granulomatosis with Polyangiitis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulomatosis with Polyangiitis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Granulomatosis with Polyangiitis Drug Sales (2021-2032) & (W Units) Figure 5. Global Granulomatosis with Polyangiitis Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Granulomatosis with Polyangiitis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Avacopan Image Figure 9. Benralizumab Image Figure 10. Rituximab Biosimilar Image Figure 11. Others Image Figure 12. Global Granulomatosis with Polyangiitis Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Granulomatosis with Polyangiitis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2021-2032) Figure 15. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Granulomatosis with Polyangiitis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Granulomatosis with Polyangiitis Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Granulomatosis with Polyangiitis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2021-2032) Figure 24. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Granulomatosis with Polyangiitis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 28. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Canada Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Mexico Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Europe Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. France Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. U.K. Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Italy Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Netherlands Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Asia Pacific Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2032) Figure 41. China Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Japan Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. South Korea Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Southeast Asia Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. India Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Australia Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South Africa Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Saudi Arabia Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Turkey Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Argentina Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. UAE Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Egypt Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Chile Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Global Granulomatosis with Polyangiitis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Granulomatosis with Polyangiitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Granulomatosis with Polyangiitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Granulomatosis with Polyangiitis Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Granulomatosis with Polyangiitis Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Avacopan
  • Benralizumab
  • Rituximab Biosimilar
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Sandoz International GmbH
  • GlaxoSmithKline Plc
  • The International Biotechnology Center (IBC) Generium
  • Panacea Biotec Ltd
  • Iltoo Pharma
  • Genor BioPharma Co Ltd
  • Coherus BioSciences Inc
  • ChemoCentryx Inc
  • Bristol-Myers Squibb Company
  • Bionovis SA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Granulomatosis with Polyangiitis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Granulomatosis with Polyangiitis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Granulomatosis with Polyangiitis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Granulomatosis with Polyangiitis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Granulomatosis with Polyangiitis Drug Market Dynamics
  1. 2.1 Granulomatosis with Polyangiitis Drug Industry Trends
  2. 2.2 Granulomatosis with Polyangiitis Drug Industry Drivers
  3. 2.3 Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges
  4. 2.4 Granulomatosis with Polyangiitis Drug Industry Restraints
3 Granulomatosis with Polyangiitis Drug Market by Manufacturers
  1. 3.1 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Granulomatosis with Polyangiitis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Granulomatosis with Polyangiitis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Granulomatosis with Polyangiitis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Granulomatosis with Polyangiitis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Granulomatosis with Polyangiitis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Granulomatosis with Polyangiitis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Granulomatosis with Polyangiitis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Granulomatosis with Polyangiitis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Granulomatosis with Polyangiitis Drug Tier 1, Tier 2, and Tier 3
4 Granulomatosis with Polyangiitis Drug Market by Type
  1. 4.1 Granulomatosis with Polyangiitis Drug Type Introduction
  2. 4.1.1 Avacopan
  3. 4.1.2 Benralizumab
  4. 4.1.3 Rituximab Biosimilar
  5. 4.1.4 Others
  6. 4.2 Global Granulomatosis with Polyangiitis Drug Sales by Type
  7. 4.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Granulomatosis with Polyangiitis Drug Revenue by Type
  11. 4.3.1 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2021-2032)
5 Granulomatosis with Polyangiitis Drug Market by Application
  1. 5.1 Granulomatosis with Polyangiitis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Granulomatosis with Polyangiitis Drug Sales by Application
  6. 5.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Granulomatosis with Polyangiitis Drug Revenue by Application
  10. 5.3.1 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2021-2032)
6 Global Granulomatosis with Polyangiitis Drug Sales by Region
  1. 6.1 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Granulomatosis with Polyangiitis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Granulomatosis with Polyangiitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Granulomatosis with Polyangiitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Granulomatosis with Polyangiitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Granulomatosis with Polyangiitis Drug Revenue by Region
  1. 7.1 Global Granulomatosis with Polyangiitis Drug Revenue by Region
  2. 7.1.1 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Granulomatosis with Polyangiitis Drug Revenue (2021-2032)
  8. 7.2.2 North America Granulomatosis with Polyangiitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Granulomatosis with Polyangiitis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Granulomatosis with Polyangiitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sandoz International GmbH
  2. 8.1.1 Sandoz International GmbH Company Information
  3. 8.1.2 Sandoz International GmbH Business Overview
  4. 8.1.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio
  6. 8.1.5 Sandoz International GmbH Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 The International Biotechnology Center (IBC) Generium
  14. 8.3.1 The International Biotechnology Center (IBC) Generium Company Information
  15. 8.3.2 The International Biotechnology Center (IBC) Generium Business Overview
  16. 8.3.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio
  18. 8.3.5 The International Biotechnology Center (IBC) Generium Recent Developments
  19. 8.4 Panacea Biotec Ltd
  20. 8.4.1 Panacea Biotec Ltd Company Information
  21. 8.4.2 Panacea Biotec Ltd Business Overview
  22. 8.4.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
  24. 8.4.5 Panacea Biotec Ltd Recent Developments
  25. 8.5 Iltoo Pharma
  26. 8.5.1 Iltoo Pharma Company Information
  27. 8.5.2 Iltoo Pharma Business Overview
  28. 8.5.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio
  30. 8.5.5 Iltoo Pharma Recent Developments
  31. 8.6 Genor BioPharma Co Ltd
  32. 8.6.1 Genor BioPharma Co Ltd Company Information
  33. 8.6.2 Genor BioPharma Co Ltd Business Overview
  34. 8.6.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
  36. 8.6.5 Genor BioPharma Co Ltd Recent Developments
  37. 8.7 Coherus BioSciences Inc
  38. 8.7.1 Coherus BioSciences Inc Company Information
  39. 8.7.2 Coherus BioSciences Inc Business Overview
  40. 8.7.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio
  42. 8.7.5 Coherus BioSciences Inc Recent Developments
  43. 8.8 ChemoCentryx Inc
  44. 8.8.1 ChemoCentryx Inc Company Information
  45. 8.8.2 ChemoCentryx Inc Business Overview
  46. 8.8.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio
  48. 8.8.5 ChemoCentryx Inc Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 8.10 Bionovis SA
  56. 8.10.1 Bionovis SA Company Information
  57. 8.10.2 Bionovis SA Business Overview
  58. 8.10.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio
  60. 8.10.5 Bionovis SA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Granulomatosis with Polyangiitis Drug Value Chain Analysis
  2. 9.1.1 Granulomatosis with Polyangiitis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Granulomatosis with Polyangiitis Drug Production Mode & Process
  6. 9.2 Granulomatosis with Polyangiitis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Granulomatosis with Polyangiitis Drug Distributors
  9. 9.2.3 Granulomatosis with Polyangiitis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst